Determinants of Weight Evolution Among HIV-Positive Patients Initiating Antiretroviral Treatment in Low-Resource Settings.

Huisin ʼt Veld, Diana; Balestre, Eric; Buyze, Jozefien; Menten, Joris; Jaquet, Antoine; Cooper, David A; Dabis, Francois; Yiannoutsos, Constantin T; Diero, Lameck; Mutevedzi, Portia; Fox, Matthew P; Messou, Eugene; Hoffmann, Christopher J; Prozesky, Hans W; Egger, Matthias; Hemingway-Foday, Jennifer J; Colebunders, Robert (2015). Determinants of Weight Evolution Among HIV-Positive Patients Initiating Antiretroviral Treatment in Low-Resource Settings. Journal of acquired immune deficiency syndromes JAIDS, 70(2), pp. 146-154. Lippincott Williams & Wilkins 10.1097/QAI.0000000000000691

Preview

Text Huisin'tVeld JAcquirImmuneDeficSyndr 2015.pdf - Published Version Available under License Publisher holds Copyright. Download (241kB) | Preview

BACKGROUND

In resource-limited settings, clinical parameters, including body weight changes, are used to monitor clinical response. Therefore, we studied body weight changes in patients on antiretroviral treatment (ART) in different regions of the world.

METHODS

Data were extracted from the "International Epidemiologic Databases to Evaluate AIDS," a network of ART programmes that prospectively collects routine clinical data. Adults on ART from the Southern, East, West, and Central African and the Asia-Pacific regions were selected from the database if baseline data on body weight, gender, ART regimen, and CD4 count were available. Body weight change over the first 2 years and the probability of body weight loss in the second year were modeled using linear mixed models and logistic regression, respectively.

RESULTS

Data from 205,571 patients were analyzed. Mean adjusted body weight change in the first 12 months was higher in patients started on tenofovir and/or efavirenz; in patients from Central, West, and East Africa, in men, and in patients with a poorer clinical status. In the second year of ART, it was greater in patients initiated on tenofovir and/or nevirapine, and for patients not on stavudine, in women, in Southern Africa and in patients with a better clinical status at initiation. Stavudine in the initial regimen was associated with a lower mean adjusted body weight change and with weight loss in the second treatment year.

CONCLUSIONS

Different ART regimens have different effects on body weight change. Body weight loss after 1 year of treatment in patients on stavudine might be associated with lipoatrophy.

Interest & Impact

Downloads

302 since deposited on 11 Feb 2016
76 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item